Paulo Naud - Concepedia

Author

Paulo Naud

Also Known As

M Lehtinen, Matti Lehtinen, Naud, Paulo, Naud, Paulo Sergio Viero, Naud, Paulo Viero, P Colares de Borba, P NAUD, P Naud, P. NAUD, P. Naud

112

Publications

Citations

H-Index

Concepts

All Affiliations

Hospital de Clínicas de Porto Alegre Universidade Estadual de Campinas (UNICAMP)Universidade Federal do Rio Grande do Sul GlaxoSmithKline (United States)GlaxoSmithKline (Belgium)

About

Paulo Naud is an author at Hospital de Clínicas de Porto Alegre specializing in medicine, public health, and cervical cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	22	6.9K
2	Public Health	16	19	3.7K
3	Health Sciences	1	1	11
4	Biostatistics	1	1	14
5	Cell Biology	1	1	66

Paulo Naud

Publications

8.5K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Jorma Paavonen, Paulo Naud, Jorge Salmerón, The Lancet As04-adjuvanted VaccineGynecologyOncogenic Hpv TypesCancer-associated VirusCervical Cancer Prevention	2009	1.6K
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler, The Lancet VaccinationVaccine SafetyVaccine DevelopmentHuman Papillomavirus VaccinesVirology	2004	1.6K
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Jorma Paavonen, David Jenkins, F. Xavier Bosch, The Lancet VaccinationVaccine SafetyInterim AnalysisPreventive MedicinePhase Iii Double-blind	2007	1.3K
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Matti Lehtinen, Jorma Paavonen, Cosette M. Wheeler, The Lancet Oncology VaccinationCervical Cancer ScreeningHpv-16/18 As04-adjuvanted VaccineCervical CancerCervical Health	2011	693
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Cosette M. Wheeler, Xavier Castellsagué, Suzanne M. Garland, The Lancet Oncology VaccinationVaccine SafetyCervical Cancer ScreeningPreventive MedicineCervical Cancer	2011	499
Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized Trial Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler, Obstetrical & Gynecological Survey ImmunologyGynecologyHpv InfectionVaccine HesitancyCervical Cancer Prevention	2005	247
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Paulo Naud, Cecília Roteli-Martins, Newton Sérgio de Carvalho, Human Vaccines & Immunotherapeutics	2014	245
Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study Unnop Jaisamrarn, Xavier Castellsagué, Suzanne M. Garland, PLoS ONE	2013	206
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine Cecília Roteli-Martins, Paulo Naud, P. De Borba, Human Vaccines & Immunotherapeutics	2012	188
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women N. De Carvalho, Júlio César Teixeira, Cecília Roteli-Martins, Vaccine VaccinologyVaccine SafetyVaccinationHpv-16/18 As04-adjuvanted VaccineCervical Cancer	2010	169

Page 1